Free Trial
NASDAQ:LFCR

Lifecore Biomedical (LFCR) Stock Price, News & Analysis

Lifecore Biomedical logo
$7.43 +0.08 (+1.09%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$7.58 +0.15 (+1.95%)
As of 07/25/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lifecore Biomedical Stock (NASDAQ:LFCR)

Key Stats

Today's Range
$7.32
$7.54
50-Day Range
$6.45
$8.78
52-Week Range
$3.68
$8.85
Volume
111,727 shs
Average Volume
197,962 shs
Market Capitalization
$275.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Lifecore Biomedical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

LFCR MarketRank™: 

Lifecore Biomedical scored higher than 16% of companies evaluated by MarketBeat, and ranked 873rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Lifecore Biomedical has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lifecore Biomedical's stock forecast and price target.
  • Earnings Growth

    Earnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.91) to ($0.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lifecore Biomedical is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lifecore Biomedical is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lifecore Biomedical has a P/B Ratio of 20.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lifecore Biomedical's valuation and earnings.
  • Percentage of Shares Shorted

    7.04% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

  • Dividend Yield

    Lifecore Biomedical does not currently pay a dividend.

  • Dividend Growth

    Lifecore Biomedical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.04% of the float of Lifecore Biomedical has been sold short.
  • Short Interest Ratio / Days to Cover

    Lifecore Biomedical has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

  • News Sentiment

    Lifecore Biomedical has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Lifecore Biomedical this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lifecore Biomedical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,824,031.00 in company stock.

  • Percentage Held by Insiders

    32.20% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lifecore Biomedical's insider trading history.
Receive LFCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter.

LFCR Stock News Headlines

Laughing Water Capital’s View on Lifecore Biomedical (LFCR)
Elon Musk: “This will transform civilization as we know it.”
Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by 2025, robots will shift from novelty to necessity — disrupting nearly every industry in their path. But one overlooked sector could become the real winner… and one little-known company may be the best way to get ahead of the boom.
Lifecore Biomedical Insider Ups Holding During Year
See More Headlines

LFCR Stock Analysis - Frequently Asked Questions

Lifecore Biomedical's stock was trading at $7.43 at the beginning of the year. Since then, LFCR stock has increased by 0.0% and is now trading at $7.43.

Lifecore Biomedical, Inc. (NASDAQ:LFCR) released its quarterly earnings data on Thursday, April, 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.05. The firm earned $35.15 million during the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative trailing twelve-month return on equity of 551.09% and a negative net margin of 35.90%.
Read the conference call transcript
.

Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lifecore Biomedical investors own include JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Visa (V).

Company Calendar

Last Earnings
4/03/2025
Today
7/25/2025
Next Earnings (Estimated)
8/15/2025
Fiscal Year End
5/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LFCR
CIK
1005286
Employees
690
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$6.00
Potential Upside/Downside
+7.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$12.01 million
Net Margins
-35.90%
Pretax Margin
-34.31%
Return on Equity
-551.09%
Return on Assets
-13.89%

Debt

Debt-to-Equity Ratio
66.36
Current Ratio
2.71
Quick Ratio
1.59

Sales & Book Value

Annual Sales
$128.26 million
Price / Sales
2.15
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.37 per share
Price / Book
20.08

Miscellaneous

Outstanding Shares
37,030,000
Free Float
25,103,000
Market Cap
$275.13 million
Optionable
Optionable
Beta
0.71
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:LFCR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners